Literature DB >> 14707966

Improved survival rates in sebaceous carcinoma of the eyelid.

M M K Muqit1, F Roberts, W R Lee, E Kemp.   

Abstract

PURPOSE: To review the clinicopathological features, management, and survival rates for patients with sebaceous gland carcinoma of the eyelid, and to analyse the reasons for improved survival.
METHODS: In the west of Scotland between 1975 and 2001, 32 cases were identified through the pathology index for sebaceous carcinoma. Pathology specimens were reviewed in all cases. The clinical data were obtained from hospital records and the database provided by the Regional Cancer Registry.
RESULTS: A total of 22 female and 10 male patients were identified. Follow-up ranged from 6 months to 15 years, median of 4.8 years. Primary treatment involved excisional techniques in 27 cases, exenteration in two cases, enucleation in two cases, and two cases required adjuvant radiotherapy. Intraepithelial spread and masquerade presentations delayed the diagnosis. Poorly differentiated tumours were associated with an unfavourable outcome. Three patients developed local tumour recurrence and one metastatic disease. In all, 10 patients died from nontumour-related causes and one died from metastatic sebaceous carcinoma. The overall tumour mortality rate in the west of Scotland was 3%.
CONCLUSIONS: From this study, patients in the west of Scotland have a better prognosis than is indicated in the literature. Astute clinical suspicion and accurate histopathological diagnosis, together with radical and aggressive surgical approaches were key factors.

Entities:  

Mesh:

Year:  2004        PMID: 14707966     DOI: 10.1038/sj.eye.6700523

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  21 in total

1.  Sebaceous gland carcinoma of the eyelid: clinicopathological features and outcome in Asian Indians.

Authors:  S Kaliki; A Ayyar; T V Dave; M J Ali; D K Mishra; M N Naik
Journal:  Eye (Lond)       Date:  2015-05-22       Impact factor: 3.775

2.  [Recurrent eyelid tumors with different dignities].

Authors:  U Löw; C S L Müller; E Zemova; F A Flockerzi; B Seitz
Journal:  Ophthalmologe       Date:  2019-11       Impact factor: 1.059

3.  Orbital exenteration: a 13 year Manchester experience.

Authors:  I Rahman; A E Cook; B Leatherbarrow
Journal:  Br J Ophthalmol       Date:  2005-10       Impact factor: 4.638

4.  American Joint Committee on Cancer T category for eyelid sebaceous carcinoma correlates with nodal metastasis and survival.

Authors:  Bita Esmaeli; Qasiem J Nasser; Hilda Cruz; Melissa Fellman; Carla L Warneke; Doina Ivan
Journal:  Ophthalmology       Date:  2012-02-11       Impact factor: 12.079

5.  Sebaceous gland carcinoma of the ocular adnexa - variability in clinical and histological appearance with analysis of immunohistochemical staining patterns.

Authors:  Eva Janine Schmitz; Martina C Herwig-Carl; Frank G Holz; Karin U Loeffler
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-07-24       Impact factor: 3.117

6.  The practice patterns in the management of sebaceous carcinoma of the eyelid in the Asia Pacific region.

Authors:  Janice J C Cheung; Bita Esmaeli; Stacey C Lam; Tracey Kwok; Hunter K L Yuen
Journal:  Eye (Lond)       Date:  2019-04-05       Impact factor: 3.775

7.  Sebaceous neoplasia and Torre-Muir syndrome.

Authors:  A J F Lazar; S Lyle; E Calonje
Journal:  Curr Diagn Pathol       Date:  2007-08

8.  [Therapy refractory blepharoconjunctivitis in a 90 year old patient].

Authors:  B Moustafa; C Wirbelauer; H Häberle; H Herbst; D T Pham
Journal:  Ophthalmologe       Date:  2007-10       Impact factor: 1.059

9.  Incidence of cutaneous sebaceous carcinoma and risk of associated neoplasms: insight into Muir-Torre syndrome.

Authors:  Graça M Dores; Rochelle E Curtis; Jorge R Toro; Susan S Devesa; Joseph F Fraumeni
Journal:  Cancer       Date:  2008-12-15       Impact factor: 6.860

10.  Immunohistochemical staining for adipophilin, perilipin and TIP47.

Authors:  K Muthusamy; G Halbert; F Roberts
Journal:  J Clin Pathol       Date:  2006-03-23       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.